12‐month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new‐onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cytokine

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cyto.2017.04.021PMID 28460256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy

  2016cited by this paper
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential

  2015cited by this paper
• Enhanced bioactive myocardial transforming growth factor-β in advanced human heart failure.

  2014cited by this paper
• Regulation of connective tissue growth factor gene expression and fibrosis in human heart failure.

  2013cited by this paper
• Changes and Prognostic Impact of Apoptotic and Inflammatory Cytokines in Patients Treated with Cardiac Resynchronization Therapy

  2013cited by this paper
• Transforming growth factor beta-1 and incidence of heart failure in older adults: the Cardiovascular Health Study.

  2012cited by this paper
• Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

  2012cited by this paper
• Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis.

  2011cited by this paper
• Systemic inflammation and cell activation reflects morbidity in chronic heart failure.

  2011cited by this paper
• Transforming growth factor (TGF)-β signaling in cardiac remodeling.

  2011cited by this paper
• Inflammatory markers as related to disease severity in patients with chronic heart failure: Limited effects of exercise training

  2011cited by this paper
• Inhibition of transforming growth factor-beta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart.

  2010cited by this paper
• Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study

  2009cited by this paper
• Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support.

  2009cited by this paper
• Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.

  2009cited by this paper
• A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats.

  2008cited by this paper
• The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.

  2007cited by this paper
• Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

  2007cited by this paper
• Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy

  2007cited by this paper
• Myocardial proteases and matrix remodeling in inflammatory heart disease.

  2006cited by this paper
• Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy: A Pilot Study

  2005cited by this paper
• Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis

  2004cited by this paper
• Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms

  2003cited by this paper
• Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.

  1999cited by this paper
• Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.

  1995cited by this paper
• The cellular basis of dilated cardiomyopathy in humans.

  1995cited by this paper
• Cardiac interstitium in health and disease: the fibrillar collagen network.

  1989cited by this paper
• Collagen Remodeling of the Pressure‐Overloaded, Hypertrophied Nonhuman Primate Myocardium

  1988cited by this paper
• Transforming Growth Factor- (cid:1) Function Blocking Prevents Myocardial Fibrosis and Diastolic Dysfunction in Pressure-Overloaded Rats

  year unknowncited by this paper
• Cellular and Molecular Life Sciences the Pathogenesis of Cardiac Fibrosis

  year unknowncited by this paper

• Circulating collagen type I fragments as specific biomarkers of cardiovascular outcome risk: Where are the opportunities?

  2025cites this paper
• THE ROLE OF GROWTH FACTORS IN THE DEVELOPMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS

  2023cites this paper
• The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized Controlled Trial

  2021cites this paper
• Relationships between circulating galectin-3, extracellular matrix fibrosis and outcomes in dilated cardiomyopathy.

  2021cites this paper
• Comparison of 12-month kinetics of serum markers of fibrosis between treatment with angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin converting enzyme inhibitor (ACE-I) in patients with heart failure with reduced ejection fraction.

  2020cites this paper
• Comparison of the 12 ‐month kinetics of the serum markers of fibrosis between treatment with angiotensin receptor–neprilysin inhibitors and angiotensin ‐converting enzyme inhibitors in patients with heart failure with reduced ejection fraction

  2020cites this paper
• Twelve-month kinetics of circulating fibrosis-linked microRNAs (miR-21, miR-29, miR-30, and miR-133a) and the relationship with extracellular matrix fibrosis in dilated cardiomyopathy

  2019cites this paper
• The role of high fat diet in the regulation of MAP kinases activity in left ventricular fibrosis.

  2019cites this paper
• Regulation of MMP and TIMP expression in synovial fibroblasts from knee osteoarthritis with flexion contracture using adenovirus-mediated relaxin gene therapy.

  2019cites this paper
• Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1.

  2018cites this paper
• Chagas Cardiomyopathy: Role of Sustained Host-Parasite Interaction in Systemic Inflammatory Burden

  2018cites this paper
• Extracellular Matrix Macromolecules as Potential Targets of Cardiovascular Pharmacotherapy.

  2018cites this paper
• Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle.

  2013cites this paper